By otakuyassine3@gmail.com 
Revvity (NYSE:RVTY – Get Free Report) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of 4.900-5.000 for the period, compared to the consensus estimate of 5.000. The company issued revenue guidance of $2.8 billion-$2.9 billion, compared to the consensus revenue estimate of $2.9 billion.
Revvity Trading Down 0.6 %
RVTY stock traded down $0.71 during mid-day trading on Friday, hitting $126.13. 349,148 shares of the company were exchanged, compared to its average volume of 863,849. The company has a quick ratio of 2.97, a current ratio of 3.56 and a debt-to-equity ratio of 0.40. The firm has a market capitalization of $15.35 billion, a P/E ratio of 60.96, a PEG ratio of 4.09 and a beta of 1.03. The business has a fifty day simple moving average of $116.60 and a 200-day simple moving average of $118.60. Revvity has a 12-month low of $97.32 and a 12-month high of $129.50.
Revvity (NYSE:RVTY – Get Free Report) last announced its earnings results on Friday, January 31st. The company reported $1.42 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.05. Revvity had a net margin of 9.34% and a return on equity of 7.42%. During the same quarter last year, the firm earned $1.25 earnings per share. On average, equities research analysts predict that Revvity will post 4.84 earnings per share for the current fiscal year.
Revvity Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Friday, May 9th. Investors of record on Friday, April 18th will be issued a $0.07 dividend. The ex-dividend date of this dividend is Thursday, April 17th. This represents a $0.28 annualized dividend and a yield of 0.22%. Revvity’s dividend payout ratio (DPR) is 13.53%.
Revvity declared that its Board of Directors has approved a stock buyback plan on Monday, November 4th that authorizes the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization authorizes the company to repurchase up to 6.5% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s leadership believes its stock is undervalued.
Analysts Set New Price Targets
RVTY has been the topic of a number of research reports. Robert W. Baird raised their target price on shares of Revvity from $136.00 to $138.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 5th. Barclays lowered their target price on shares of Revvity from $140.00 to $135.00 and set an “overweight” rating on the stock in a research report on Monday, November 25th. Sanford C. Bernstein lowered shares of Revvity from an “outperform” rating to a “market perform” rating and set a $130.00 target price on the stock. in a research report on Friday, January 10th. Leerink Partners raised their target price on shares of Revvity from $130.00 to $135.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Finally, TD Cowen raised their target price on shares of Revvity from $141.00 to $144.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Five analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $132.00.
Read Our Latest Stock Report on RVTY
Insider Transactions at Revvity
In related news, insider Tajinder S. Vohra sold 5,492 shares of the business’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $116.81, for a total value of $641,520.52. Following the sale, the insider now owns 19,652 shares of the company’s stock, valued at $2,295,550.12. The trade was a 21.84 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.60% of the stock is owned by insiders.
About Revvity
Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
Recommended Stories
Receive News & Ratings for Revvity Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Revvity and related companies with MarketBeat.com’s FREE daily email newsletter.